Endocrine Abstracts

Objectives: The European Network for the Investigation of Gender Incongruence (ENIGI) is a multicenter prospective cohort study. All participants receive a standardized gender affirming treatment protocol including regular follow-up visits. The current study compared the changes in androgens upon starting hormone treatment and during follow-up in transgender women (TW) with or without gonadectomy by investigating serum total (TT), calculated free testosterone (cFT), DHEA, DHEA...

ObjectivesThe European Network for Investigation of Gender Incongruence (ENIGI) is a multicenter prospective cohort study. All participants receive a standardized gender affirming treatment (GAHT) protocol including regular follow-up. The current study compared changes in androgens upon starting GAHT and during follow-up in transgender women (TW) with or without gonadectomy by investigating serum total testosterone (TT), calculated free testosterone (cFT...

Introduction: Transgender women on gender-affirming hormone therapy (GAHT) with estrogens and anti-androgens have low serum androgen levels. These low levels may be associated with clinical symptoms such as depressed mood, reduced sexual desire and tiredness. Whether androgen levels change over the course of anti-androgen use and after gonadectomy, in a context of unchanged estrogen treatment, remains to be elucidated.Methods: This study is part of the E...

Background: Persistent vaginal bleeding can be psychologically stressful and incongruent with gender identity in transgender men (assigned female at birth with male gender identity). Previous studieshave cross-sectionally described amenorrhea in cohorts of transgender men on intramuscular or subcutaneous testosterone injections. It remains uncertain which testosterone preparations most effectively suppress vaginal bleeding and when amenorrhea occurs after testosterone initiati...

In mammals, the gonads and the brain develop from bipotential organs that will differentiate into female or male organs, during a critical period of development. This process begins with the production of testosterone by the testes, which will be converted into estradiol in the brain, by the aromatase. While the end is defined by the moment when the inhibition of androgens (in males), or treatment with estrogens (in females), stops having an effect on brain dimorphism. But in ...